Drugs / GSK1358820
GSK1358820
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 3 met primary | ||||||
| Phase 3 | NCT02849418 | Oct 2016 → Mar 2018 | overactive bladder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT02820844 | Aug 2016 → Mar 2018 | overactive bladder | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT01153815 | Apr 2010 → Jun 2011 | stroke disorder | GlaxoSmithKline | Completed | Met primary |
| Comparator or background therapy4 trials | ||||||
| Phase 3 | NCT01584843 Comparator | May 2012 → Jul 2013 | strabismus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01128738 Comparator | Apr 2010 → Aug 2011 | isolated hyperchlorhidrosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00460655 Comparator | May 2007 → Dec 2008 | stroke disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00460564 Comparator | May 2007 → Dec 2008 | stroke disorder | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-03-29 | AbbVie | Results AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting abbvie.com ↗
Neutralizing Antibody Conversion with OnabotulinumtoxinA from Global Studies Across Multiple Indications in nearly 30,000 Patient Records: A Meta-Analysis |
| 2021-02-10 | AbbVie | Regulatory BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition abbvie.com ↗ |
All press releases naming this drug 13 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1358820 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01584843 ↗ |
| Known as | BOTOX | “GSK1358820 (hereinafter, referred to as BOTOX®)” NCT01128738 ↗ |
| Known as | Botulinum Toxin Type A | “A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Overactive Bladder” NCT02820844 ↗ |
| Modality | Protein / enzyme biologic | “Botulinum Toxin Type A” NCT01153815 ↗ |
| Route | Other | “as intradermal injections” NCT01128738 ↗ |